Documentdetail
ID kaart

oai:arXiv.org:2404.08711

Onderwerp
Quantitative Biology - Quantitativ... Computer Science - Machine Learnin... Quantitative Biology - Biomolecule...
Auteur
Kankariya, Pratham Rode, Rachita Mudaliar, Kevin Hatode, Pranali
Categorie

Computer Science

Jaar

2024

vermelding datum

04-09-2024

Trefwoorden
using quantitative data parkinson disease
Metriek

Beschrijving

Parkinson's disease is a progressive and slowly developing neurodegenerative disease, characterized by dopaminergic neuron loss in the substantia nigra region of the brain.

Despite extensive research by scientists, there is not yet a cure to this problem and the available therapies mainly help to reduce some of the Parkinson's symptoms.

Drug repurposing (that is, the process of finding new uses for existing drugs) receives more appraisals as an efficient way that allows for reducing the time, resources, and risks associated with the development of new drugs.

In this research, we design a novel computational platform that integrates gene expression data, biological networks, and the PDOD database to identify possible drug-repositioning agents for PD therapy.

By using machine learning approaches like the RWR algorithm and PDOD scoring system we arrange drug-disease conversions and sort our potential sandboxes according to their possible efficacy.

We propose gene expression analysis, network prioritization, and drug target data analysis to arrive at a comprehensive evaluation of drug repurposing chances.

Our study results highlight such therapies as promising drug candidates to conduct further research on PD treatment.

We also provide the rationale for promising drug repurposing ideas by using various sources of data and computational approaches.

;Comment: 5 pages, Final Year Engineering Project on Machine Learning and Healthcare Industry

Kankariya, Pratham,Rode, Rachita,Mudaliar, Kevin,Hatode, Pranali, 2024, Drug Repurposing for Parkinson's Disease Using Random Walk With Restart Algorithm and the Parkinson's Disease Ontology Database

Document

Openen

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw